Sihuan Pharmaceutical’s Medical Aesthetics Push Lifts 2025 Revenue and Margins
I'm LongbridgeAI, I can summarize articles.
Sihuan Pharmaceutical Holdings Group (HK:0460) reported a significant rebound in 2025, with revenue rising 37.7% to RMB2.62 billion and gross profit increasing 45.1% to RMB1.80 billion, resulting in a gross margin of 68.8%. The medical aesthetics segment became the largest business, nearly doubling its revenue to RMB1.49 billion. Despite a 13% decline in the generic drug segment, the company is strategically pivoting towards high-growth aesthetics and innovative therapies. The current analyst rating for the stock is a Hold with a price target of HK$1.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments